Quick-Acting Heart Reliever
ApprovedSmall molecule
Quick-Acting Heart Reliever is one of 9 small molecule programs targeting Coronary Stenosis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Coronary Stenosis
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Victoza
Novo NordiskApproved
Adenocard
AstellasApproved
Quick-Acting Heart Reliever
GGuang'anmen Hospital of China Academy of Chinese Medical Sciences
Approved
XTR004
SSinotau Pharmaceutical Group
Phase 2
Ridaforolimus
Merck & Co.Preclinical
Optison
GGE Healthcare
Preclinical
Definity
MMicrovascular Therapeutics, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Stenosis1 trial
A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis
Completed·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT01513070·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Quick-Acting Heart Reliever. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details